{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:21:52Z","timestamp":1761157312974,"version":"3.44.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.medcli.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:50:27Z","timestamp":1644879027000},"page":"615-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gota. \u00bfQu\u00e9 hay de nuevo, doctor?"],"prefix":"10.1016","volume":"158","author":[{"given":"Fernando","family":"P\u00e9rez Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"P\u00e9rez Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Gantes Pedraza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2022.01.002_bib0305","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jbspin.2017.03.013","article-title":"Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study","volume":"85","author":"Maravic","year":"2018","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.medcli.2022.01.002_bib0310","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: Why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.002_bib0315","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40744-017-0091-1","article-title":"Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice","volume":"5","author":"Perez-Ruiz","year":"2018","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0320","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s12325-012-0059-z","article-title":"Evaluation and treatment of gout as a chronic disease","volume":"29","author":"Perez-Ruiz","year":"2012","journal-title":"Adv Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0325","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12576-018-00658-1","article-title":"Identification of the multivalent PDZ protein PDZK1 as a binding partner of sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8) and SMCT2 (SLC5A12)","volume":"69","author":"Srivastava","year":"2019","journal-title":"J Physiol Sci."},{"key":"10.1016\/j.medcli.2022.01.002_bib0330","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/acr.22746","article-title":"Computational lexical analysis of the language commonly used to describe gout","volume":"68","author":"Edwards","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0335","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","article-title":"Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout","volume":"78","author":"Bursill","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.002_bib0340","first-page":"152","article-title":"Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases","volume":"89","author":"Quilis","year":"2021","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.medcli.2022.01.002_bib0345","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00296-015-3242-0","article-title":"Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients","volume":"35","author":"Perez-Ruiz","year":"2015","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.medcli.2022.01.002_bib0350","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13075-021-02444-8","article-title":"The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: Diet has a weak causal effect","volume":"23","author":"Topless","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0355","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/rheumatology\/kez685","article-title":"Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus","volume":"59","author":"Zaidi","year":"2020","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2012.08.012","article-title":"Gout: The mechanism of urate crystal nucleation and growth. A hypothesis based in facts","volume":"80","author":"Pascual","year":"2013","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.medcli.2022.01.002_bib0365","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.medcli.2022.01.002_bib0370","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.semnephrol.2020.12.001","article-title":"Pathophysiology of gout","volume":"40","author":"Narang","year":"2020","journal-title":"Semin Nephrol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0375","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/art.39581","article-title":"Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study","volume":"68","author":"Andr\u00e9s","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0380","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.002_bib0385","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.002_bib0390","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.002_bib0395","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/rheumatology\/keaa366","article-title":"Ultrasound for the diagnosis of gout-the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group","volume":"60","author":"Christiansen","year":"2021","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0400","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s42358-021-00194-4","article-title":"Gout of feet and ankles in different disease durations: Diagnostic value of single-source DECT and evaluation of urate deposition with a novel semiquantitative DECT scoring system","volume":"61","author":"Shang","year":"2021","journal-title":"Adv Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0405","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.berh.2016.10.010","article-title":"Imaging of gout: New tools and biomarkers?","volume":"30","author":"Araujo","year":"2016","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0410","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Brief report: Validation of a definition of flare in patients with established gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0415","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/acr.23926","article-title":"Coexistent hyperuricemia and gout in rheumatoid arthritis: Associations with comorbidities, disease activity, and mortality","volume":"72","author":"Chiou","year":"2020","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0420","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: A randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.01.002_bib0425","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2147\/TCRM.S162956","article-title":"Improving adherence to gout therapy: An expert review","volume":"14","author":"Perez-Ruiz","year":"2018","journal-title":"Ther Clin Risk Manag."},{"key":"10.1016\/j.medcli.2022.01.002_bib0430","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40744-020-00249-w","article-title":"High rate of adherence to urate-lowering treatment in patients with gout: Who's to blame?","volume":"7","author":"Perez-Ruiz","year":"2020","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0435","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/art.1780341203","article-title":"Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout","volume":"34","author":"McCarthy","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.002_bib0440","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.medcli.2022.01.002_bib0445","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.002_bib0450","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14397595.2020.1825053","article-title":"Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy \u2014a study using dual-energy computed tomography","volume":"31","author":"Chui","year":"2021","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0455","first-page":"ii9","article-title":"Treating to target: A strategy to cure gout","volume":"48 Suppl 2","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0460","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2022.01.002_bib0465","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A two-stage approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.002_bib0470","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22741","article-title":"Development of preliminary remission criteria for gout using delphi and 1000 minds consensus exercises","volume":"68","author":"De Lautour","year":"2016","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0475","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.191242","article-title":"Flare rate thresholds for patient assessment of disease activity states in gout","volume":"48","author":"Taylor","year":"2021","journal-title":"J Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0480","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","article-title":"Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase","volume":"20","author":"Mandell","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0485","doi-asserted-by":"crossref","first-page":"e001015","DOI":"10.1136\/rmdopen-2019-001015","article-title":"Failure to reach uric acid target of <0.36 mmol\/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality","volume":"5","author":"P\u00e9rez Ruiz","year":"2019","journal-title":"RMD Open."},{"key":"10.1016\/j.medcli.2022.01.002_bib0490","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2022.01.002_bib0495","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","article-title":"Improving cardiovascular and renal outcomes in gout: What should we target?","volume":"10","author":"Richette","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0500","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0505","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40744-017-0082-2","article-title":"Treatment with allopurinol is associated with lower risk of acute kidney injury in patients with gout: A retrospective analysis of a nested cohort","volume":"4","author":"Perez-Ruiz","year":"2017","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0510","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","article-title":"Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts","volume":"86","author":"Perez-Ruiz","year":"2000","journal-title":"Nephron."},{"key":"10.1016\/j.medcli.2022.01.002_bib0515","series-title":"Medical genetics summaries [Internet]","article-title":"Allopurinol therapy and HLA-B*58:01 genotype","author":"Dean","year":"2012"},{"issue":"Suppl 1","key":"10.1016\/j.medcli.2022.01.002_bib0520","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/rheumatology\/kex422","article-title":"How to prevent allopurinol hypersensitivity reactions?","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0525","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-018-1755-0","article-title":"How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose","volume":"20","author":"Stamp","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0530","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2022.01.002_bib0535","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"J Clin Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0540","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/acr.20221","article-title":"Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout","volume":"62","author":"Perez-Ruiz","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0545","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.bbadis.2018.03.009","article-title":"Benzbromarone aggravates hepatic steatosis in obese individuals","volume":"1864","author":"Sun","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"10.1016\/j.medcli.2022.01.002_bib0550","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10157-021-02115-7","article-title":"Comparative study of a novel selective urate reabsorption inhibitor \u201cdotinurad\u201d among patient groups with different stages of renal dysfunction","volume":"25","author":"Takahashi","year":"2021","journal-title":"Clin Exp Nephrol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0555","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2022.01.002_bib0560","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0565","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase iii trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther."},{"key":"10.1016\/j.medcli.2022.01.002_bib0570","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safetystudy","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.medcli.2022.01.002_bib0575","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.002_bib0580","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/1744666X.2014.880653","article-title":"Canakinumab for gout: A specific, patient-profiled indication","volume":"10","author":"Perez-Ruiz","year":"2014","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0585","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A randomized phase ii study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2022.01.002_bib0590","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00296-020-04659-5","article-title":"Adrenocorticotropic hormone: An effective \u201cnatural\u201d biologic therapy for acute gout?","volume":"40","author":"Daoussis","year":"2020","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.medcli.2022.01.002_bib0595","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.10526","article-title":"Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis","volume":"46","author":"Getting","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2022.01.002_bib0600","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101003","article-title":"Understanding the patient voice in gout: A quantitative study conducted in Europe","volume":"4","author":"De Meulemeester","year":"2020","journal-title":"BJGP Open."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775322000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:54:39Z","timestamp":1758419679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775322000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0025775322000033"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2022.01.002","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gota. \u00bfQu\u00e9 hay de nuevo, doctor?","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}